Physician profile
Usha Niranjan
NPI 1396733077
$1,003.60
in general payments reported to CMS, 2019-2025
25 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $102 · 2023: $262 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $423.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $123.15 | 2019-2025 | Imfinzi, Enhertu |
| Novartis Pharmaceuticals Corporation | $90.77 | 2019-2023 | |
| Daiichi Sankyo INC. | $78.16 | 2019-2025 | Enhertu, Vanflyta, Injectafer |
| Merck Sharp & Dohme LLC | $76.96 | 2019-2025 | Keytruda, Keytruda Qlex |
| Bayer Healthcare Pharmaceuticals INC. | $64.59 | 2019-2025 | |
| Amgen INC. | $61.11 | 2019 | |
| Pfizer INC. | $59.76 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.87 | 2019-2023 | Gilotrif |
| Genentech USA, INC. | $42.74 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $40.03 | 2019 | |
| Lilly USA, LLC | $37.38 | 2019-2023 | Verzenio |
| Pharmacyclics LLC, An Abbvie Company | $29.25 | 2019 | |
| Incyte Corporation | $28.79 | 2019 | |
| Genzyme Corporation | $28.61 | 2019 | |
| Mirati Therapeutics, INC. | $25.67 | 2023 | Krazati |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $25.04 | 2023 | |
| Adaptive Biotechnologies Corporation | $24.99 | 2025 | Clonoseq |
| Astellas Pharma US INC | $22.43 | 2023 | Xtandi |
| Abbvie INC. | $18.29 | 2025 | |
| Taiho Oncology, INC. | $14.85 | 2019 | |
| Janssen Biotech, INC. | $14.71 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.15 | 2020 | |
| Eisai INC. | $13.85 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.00 | 2020 | |
| Kite Pharma, INC. | $12.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usha Niranjan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.